Ironwood Pharmaceuticals (IRWD) Accumulated Expenses (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Accumulated Expenses across 17 years of filings, most recently posting $27.9 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $27.9 million, up 434.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.9 million (up 434.85% YoY), and the FY2025 annual result was $4.4 million, down 83.47% from the prior year.
• Accumulated Expenses came in at $27.9 million for Q1 2026 at Ironwood Pharmaceuticals, up from $4.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $79.6 million in Q2 2023 to a low of $2.1 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $12.3 million (2022), against an average of $17.3 million.
• Across the five-year window, Accumulated Expenses soared 1193.99% in 2022 and sank 94.47% in 2024, its largest moves.
• Ironwood Pharmaceuticals' Accumulated Expenses stood at $16.7 million in 2022, then soared by 164.99% to $44.3 million in 2023, then sank by 39.33% to $26.8 million in 2024, then slumped by 83.47% to $4.4 million in 2025, then jumped by 528.87% to $27.9 million in 2026.
• The last three Accumulated Expenses figures came in at $27.9 million (Q1 2026), $4.4 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.